Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.3333.

NBTX has been the topic of several research reports. Leerink Partners upped their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, UBS Group upped their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NBTX. Royal Bank of Canada lifted its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Marshall Wace LLP acquired a new stake in Nanobiotix in the fourth quarter worth about $220,000. Finally, Millennium Management LLC acquired a new stake in Nanobiotix in the fourth quarter worth about $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Trading Up 7.2%

Shares of NBTX opened at $44.50 on Thursday. The stock has a fifty day moving average price of $38.97 and a two-hundred day moving average price of $35.90. Nanobiotix has a 52-week low of $8.03 and a 52-week high of $57.14.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.